Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: Trends in etiology in 310 episodes

Diagnostic Microbiology and Infectious Disease

Volumn 36, Issue 1, 2000, Pages 7-11

  Krčméry Jr , Vladimír ^a   Kovačičová, Gabriela ^a  

^a TRNAVA UNIVERSITY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD CULTURE; CANDIDA; CRYPTOCOCCUS; FUNGEMIA; FUNGUS IDENTIFICATION; FUSARIUM; GROWTH; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHODOTORULA; SLOVAKIA; TRICHOSPORON;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; FUNGEMIA; FUNGI; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; SLOVAKIA;

EID: 0033966250     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00096-6     Document Type: Article

References (42)

1. Abele-Horn M., Kopp U., Sternberg A., Ohly A., Dauber W., Russwurm W., Büchinger O., Nagengast P. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection. 6:1996;426-432.
2. Abi-Said D., Annaisie E., Uzun D., Raad I., Pinczowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 24:1997;1122-1128.
3. Anaissie E.J., Bodey G.P. Trichosporonosismeeting the challenge. Eur J Clin Microbiol Infect Dis. 9:1991;711-720.
4. Beck Sague C.M., Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Surveillance System. J Infect Dis. 167:1993;1247-1251.
5. Bow E.J. Documented fungal infections after chemotherapy for acute leukemia. Clin Infect Dis. 24:1997;394-401.
6. Bow E.J., Loewen R., Cheang M.S., Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia; The pathogenetic role of the antileukemic regimen. Clin Infect Dis. 21:1995;361-369.
7. Demitrovicova A., Kralovicova K. Bacteremia and fungaemia after antineoplastic chemotherapyassociation between cytotoxics and particular pathogerus. Anti-infect Drugs Chemother. 3:1997;26-28.
8. Edwards J.E. Jr. Should all patients with candidemia be treated with antifungal agents? Clin Infect Dis. 15:1992;422-423.
9. Ellis P., Spence D. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematologic malignancies. Eur J Clin Microbiol Infect Dis. 1:1994;3-11.
10. Foltan, V. (1999). Consumption of antibiotics in Slovakia in 1997-1998 (in Slovak). State Institute of Drug Control. Bratislava, p. 25.
11. Fraser V.J., Jones M., Dunkel J., Storfer S., Medoff G., Dunagan W.C. Candidemia in a tertiary care hospital Epidemiology, risk factors and predictors of mortality . Clin Infect Dis. 15:1992;414-421.
12. Goldman M., Pottage J., Weaver D.C. Candida krusei fungaemia. Medicine. 3:1993;143-150.
13. BMT Cooperative Group , Goodman J., Winston D.J., Greenfield R.A. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 326:1992;845-851.
14. Guiot H.F.L., Fibbe W.E., van't Wout J.W. Risk factors for fungal infections in patients with malignant hematological disorders Implications for empirical therapy and prophylaxis . Clin Infect Dis. 18:1994;525-532.
15. Harvey R.L., Myers J.P. Nosocomial fungaemia in a large community teaching hospital. Arch Intern Med. 147:1987;2117-2120.
16. Horn R., Wong B., Kiehn T.E., Armstrong D. Fungaemia in a cancer hospital changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 7:1985;645-655.
17. Huttova M., Filka J., Kurak J., Kralinsky K., Krcmery V. Jr. Candida fungaemia in neonates. Pediatr Infect Dis J. 17:1998;1112-1116.
18. Karabinis A., Hils C., Leclercq B., Tancrede C., Baume D., Andremont A. Risk factors for candidemia in cancer patients A case-control study . J Clin Microbiol. 33:1988;1467-1470.
19. Kim-Stamos J., Rowley A.H. Candidaemia in a paediatric population. Clin Infect Dis. 20:1995;571-575.
20. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II A severity of disease classification system . Crit Care Med. 13:1985;818-829.
21. Komshian S.V., Uwaydah A.K., Sobel J.D., Crane L.R. Fungaemia caused by Candida species and Torulopsis glabrata in the hospitalized patient Frequency, characteristics, and evaluation of factors influencing outcome . Rev Infect Dis. 11:1989;379-390.
22. Kunova A., Trupl J., Spanik S., Drgona L., Sufliarsky J., Lacka J., Studena M., Grey E., Studena V., Kukuckova E., Kollar T., Pichna P., Oravcova E., Krcmery V. Jr. Candida glabrata, Candida krusei, non-albicans Candida spp. and other fungal organisms in a sixty bed National Cancer Center in 1989-1993 No Association with the Use of Fluconazole . Chemotherapy. 41:1995;39-44.
23. Lecciones J.A., Lee J.W., Navarro E.E. Vascular catheterassociated fungemia in patients with cancer Analysis of 155 episodes . Clin Infect Dis. 14:1992;875-883.
24. McQuillen D., Zingman S.B., Meunier F., Levitz S. Invasive infections due to C. krusei. Clin Infect Dis. 14:1992;472-478.
25. Nguyen H.M., Peacock J.E., Tanner D.C., Morris A.J., Snydman D.R., Wadener M.M., Yu V.L. Therapeutic approach in patients with candidemia. Arch Intern Med. 11:1995;2429-2438.
26. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infections due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis. 31:1998;327-332.
27. SCOPE Participant Group , Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infections due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis. 30:1998;121-129.
28. Pfaller M.A., Messer S.A., Houston A., Rangel-Frausto M.S., Wiblin T., Blumberg H.M., Edwards J.E., Jarvis W., Martin M.A., Neu H.C., Saiman L., Patterson J.E., Dibb J.C., Roldam C.M., Rinaldi M.G., Wenzel R.P. National epidemiology of mycoses survey A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species . Diagn Microbiol Infect Dis. 31:1998;289-296.
29. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Doern G.V., Brandt M.E., Hajjeh R.A. Trends in species distribution and susceptibility to fluconazole among bloodstream isolates of Candida species in the United States. Diagn Microbiol Infect Dis. 33:1999;217-222.
30. Candidemia Study Group , Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., van der Horst C.M., Edwards J.E., Washburn R.G., Scheld W.M., Karchmer A.W., Dine A.P., Levenstein M.J., Webb C.D. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia. N Engl J Med. 331:1994;1325-1330.
31. Rex J.H., Rinaldi M.G., Pfaller M.A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 39:1995;1-8.
32. Norwegian Yeast Study Group , Sandven P., Bevanger L., Digranes A., Gaustand P., Haukland H.H., Steinbaak M. Constant low rate of fungaemia in Norway, 1991 to 1996. J Clin Microbiol. 36:1998;3455-3459.
33. Van't Wout J.W. Fluconazole in treatment of Candida infections caused by non-albicans species. Eur J Clin Microbiol Infect Dis. 15:1996;362-363.
34. Verweij P.E., Donelly J.P., Kullberg B.J., Meis J.F.G.M., De Pauw B.E. Amphotericin B versus amphotericin B plus 5-flucytosine Poor results in the treatment of proven systemic mycoses in neutropenic patients . Infection. 22:1994;81-85.
35. Invasive Fungal Infection Group of the EORTC , Viscoli C., Girmenia C., Marinus A., Collette L., Martino F., vandercam B., Doyen C., Lebeau B., Spence D., Krcmery V., De Pauw B., Meunier F. Candidemia in cancer patients A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) . Clin Infect Dis. 28:1999;1071-1079.
36. Voss A., Kluytmans J.A.J.W., Koeleman J.G.M., Spanjaard L., Vandenbroucke-Grauls C.M.J.E., Verbrugh H.A., Vos M.C., Weersink A.Y.L., Hoogkamp-Korstajne J.A.A., Meis J.F.G.M. Occurrence of yeasts bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis. 15:1996;909-912.
37. Voss A., Le Noble J.L.M.L., Verduyn Lunel F.M., Foudraine N., Meis J.F.G.M. Candidemia in intensive care unit patients Risk factors for mortality . Infection. 25:1997;8-11.
38. Walsh T., Pizzo P. Fungaemia in HIV-positive children. Clin Infect Dis. 20:1996;732-740.
39. Wenzel R.P. Nosocomial candidemia Risk factors and attributable mortality . Clin Infect Dis. 20:1995;1531-1534.
40. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 148:1988;2642-2645.
41. White M. Epidemiology of invasive candidiasis. Int J Infect Dis. 51:1997;7-10.
42. Wingard J.R. Importance of Candida species other than C. albicans. Antimicrob Agents Chemother. 12:1995;133-139.